n.a. (CVD)

106.42
NYSE
Prev Close 106.42
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.00 / 0.00
Exchange NYSE
Div & Yield N.A. (N.A)
Ahead Of The Bell: Covance Upgraded After Slide

Ahead Of The Bell: Covance Upgraded After Slide

Analyst upgrades Covance on good results for clinical unit and fairer preclinical expectations

Phase Forward Buys Covance Business

Phase Forward Buys Covance Business

Phase Forward completes $10 million deal for Covance business

Analysts' Upgrades, Downgrades: Cisco

See who made what calls.

Cramer's 'Mad Money' Recap: Oct. 25

A stronger dollar is cushioning the U.S. markets from the volatility in overseas markets, Cramer says.

'Fast Money' Portfolios of the Week

'Fast Money' Portfolios of the Week

Here's what the crew's been talking about lately.

Health Winners & Losers: Lincare

Lincare lifts on an upgrade.

Health Winners & Losers: Crucell

Health Winners & Losers: Crucell

Crucell climbs on a new supply deal in its drug development plans.

A Safer Way to Play the Drug Sector

Contract research organizations aren't without risks of course, but they do offer some protection against the vagaries of the industry.

Jim Cramer's Portfolios of the Week

These are the stocks Cramer's been talking about lately.

Cramer's 'Mad Money Lightning Round': Take State Street

The investment services company deserves to go higher, Cramer says.

Cramer's 'Mad Money' Recap: Get In the GameStop

Cramer says the company can capitalize on the older video-game player.

Cramer's 'Mad Money Lightning Round': Goldman Savvy on Credit Crunch

Cramer says the brokerage firm is the only one that handled the mortgage mess right.

Wednesday's Analysts' Upgrades and Downgrades

Who made what calls.

Monday's Analysts' Upgrades and Downgrades

Who made what calls.

Cramer's 'Mad Money Lightning Round': Don't Rag on Rite Aid

Cramer likes the drugstore chain despite what he considers an ill-advised downgrade.

Thursday's Analysts' Upgrades and Downgrades

Who made what calls.

Testing for Value in Outsourced R&D

You can find quality in firms that do outsourced drug trials, but pick your spots and know the risks.

Covance Earnings Rise

The second quarter beats by a penny.

Covance Gets $187 Million Contract

Covance Gets $187 Million Contract

The contract is the largest in the drug research company's history.

Covance Completes Radiant Buy

Covance Completes Radiant Buy

The deal involves eight sites.

Covance Profit Rises

Shares tumble 5%.

Scandal-Hit Name May Still Have Game

Allegations of questionable practices have battered drug-testing firm SFBC, but it's on track for growth.

Taking the Long Side of SFBC Battle

SFBC has been targeted by the media and Congress. But it's still a reasonable speculative buy.

Not Near a Bottom

Wednesday's head fake couldn't hide the fact that we were overbought.

Year to Date, Gurus Outrun the Pack

The stocks recommended in this column have handily beat the S&P 500.

More Downside After a Small Plateau

Expect a few days of swings around this level, and then as we approach month-end, a drop.

Covance Exhibits Financial Wellness

Shares of the drug-development services company get a clean bill of health.

Value and Growth Converge in Covance

There's a lot to like about this provider of research services.

Get the Medicine Over With

The indices could test their 200-day exponential moving average before this correction ends.

Evidence Grows for Market Pullback

The Arms Index shows an even more overbought condition than last week.